Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:5/7/2009

e to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Cadence(TM), Acetavance(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc.

    Contacts:   William R. LaRue
                SVP & Chief Financial Officer
                Cadence Pharmaceuticals, Inc.
                858-436-1400


                          CADENCE PHARMACEUTICALS, INC.
                          (a development stage company)
                       CONDENSED STATEMENTS OF OPERATIONS
                                  (unaudited)

                                                  Three Months Ended
                                                        March 31,
                                                  2009            2008
    Operating expenses:
      Research and development                $6,139,342    $10,478,047
      Marketing                                  536,115        583,702
      General and administrative               2,811,747      2,667,038
      Other                                      650,786         28,257
        Total operating expenses              10,137,990     13,757,044

    Loss from operations                     (10,137,990)   (13,757,044)

    Other (expense) income, net                 (299,373)        40,129

    Net loss                                $(10,437,363)  $(13,716,915)

    Basic and diluted net loss per share(1)       $(0.24)        $(0.42)

    Shares used to compute basic and
    diluted net loss per share(1)             43,831,889     32,921,093

    (1) As a result of the issuance of 12,039,794 shares of common stock
        pursuant to a private placement in the first quarter of 2009 and
        9,240,307 shares of common stock pursuant to an effective shelf
        registration in the first qu
'/>"/>
SOURCE  Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 

Related biology technology :

1. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
2. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
4. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIOCOM Investor Conference
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the JMP Securities Third Annual Healthcare Focus Conference
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
11. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Leerink Swann Pain Roundtable Conference on June 23, 2008 in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)SAN FRANCISCO, Dec. 3 VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today anno
(Date:12/3/2009)NEW DELHI, India, Dec. 3 /PRNewswire-Asia/ -- Dr. Susan Jiang, M.D., Ph.D.,Chief Science Officer at Shenzhen Beike Biotechnology Co. Ltd.,( http://www.beikebiotech.com ), spoke at a conference on Hig
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Drug Discovery Technologies - A Global Update of Market Trends & Opportunities ,,
(Date:12/2/2009)LIBREVILLE, Gabon, December 2 , - "Bolstering Biodiversity in Africa: Everyone,s Problem and Heritage" , Coinciding with the International Year of Biodiversity, 2-3 June 2010 the,Gabonese Rep
Breaking Biology Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9Libreville International Conference 2-3 June 2010 2
...v. 7 InterMune, Inc.,(Nasdaq: ITMN ) today annou...ve Officer and President of InterMune, will presen... November 11, 2008 at 4:00 p.m. EST., To access a... and other,interested parties may log on to the in...site at http://www.intermune.com . The company re...
... 7 Human Genome Sciences,Inc. (Nasdaq: HGSI ) an...e,Bank Biotech Boston Confab will be webcast and m... http://www.newscom.com/cgi-bin/prnh/20080416/HGSL... management team will present,a corporate overview...Time., Investors interested in listening to the l...
...ov. 7 Cepheid (Nasdaq:,CPHD) today announced that...investor conferences, and invited investors to par...Health Care Conference, Phoenix, AZ Friday, N...Piper Jaffray Health Care Conference, New York, NY...rn Time Accessing Webcasts, To access the live w...
Other Biology Technology:Cepheid to Webcast Upcoming Financial Presentations 2
(Date:12/2/2009)PHILADELPHIA People who smoke their first cigarette within minutes after waking up have much higher levels of cotinine, a by-product of nicotine when processed by the body, than those who wait to smo
(Date:12/2/2009)PHILADELPHIA Assurance of a cancer-free status did not prompt people participating in a long-term computerized tomography (CT) lung-cancer screening program to pick up their cigarettes again, researc
(Date:12/2/2009)Researchers from the University of Georgia College of Veterinary Medicine have made an "unexpected" dual discovery that could open new avenues for treating Ichthyophthirius multifiliis, or "Ich", a de
Breaking Biology News(10 mins):Increased nicotine levels detected in those who light-up earlier 2Repeat negative CT scan for lung cancer does not encourage ex-smokers to resume the habit 2UGA researchers lead team in discovery involving devastating freshwater fish parasite, 'Ich' 2UGA researchers lead team in discovery involving devastating freshwater fish parasite, 'Ich' 3E Cigarettes Pose a Health Hazard FDA Warns 52474 1E Cigarettes Pose a Health Hazard FDA Warns 52474 2E Cigarettes Pose a Health Hazard FDA Warns 52474 3FDA Acts to Protect Public Health from Electronic Cigarettes 52470 1FDA Acts to Protect Public Health from Electronic Cigarettes 52470 2FDA Acts to Protect Public Health from Electronic Cigarettes 52470 3Medifast Independent Director Lt Gen Dennis McCarthy Confirmed as Assistant Secretary of Defense for Reserve Affairs 52466 1Medifast Independent Director Lt Gen Dennis McCarthy Confirmed as Assistant Secretary of Defense for Reserve Affairs 52466 2Medifast Independent Director Lt Gen Dennis McCarthy Confirmed as Assistant Secretary of Defense for Reserve Affairs 52466 3
...Ariz. Sept. 15, 2008 Investigators at the Transl...nnounced a link between the brain protein KIBRA an... to promising new treatments for this memory-robbi...ious TGen-led study published in the prestigious j...n KIBRA and memory in healthy adults. , In the ne...
...ections indicating that more than 50% of all osteo...ar 2050, the prevention and treatment of osteoporo... the region. , The IOF World Congress on Osteopor...sia, is an ideal opportunity for health profession...gress devoted to all aspects of osteoporosis and r...
...searchers have found that a gene variant known to ...ldren plays a similar role in white American child... most common chronic illness among children in the...hich a variety of genes are thought to interact wi... produce its effects. As in many other genetic dis...
Other Biology News:International TGen-led team finds link between brain protein and Alzheimer's disease 2International TGen-led team finds link between brain protein and Alzheimer's disease 3International TGen-led team finds link between brain protein and Alzheimer's disease 4IOF World Congress on Osteoporosis in Bangkok to address Asian issues 2More findings on gene involved in childhood asthma 2
Coating Solution Concentrate Kit from KPL
Flashlight-Trigger Solution from Assay Designs/Stressgen Bioreagents
...n 2-color real-time PCR detection system holds 48 ...of 48 LEDs independently excites fluorescence (470...todiodes detects emitted light (523-543 nm and 540...ers of the MJ Mini thermal cycler. System dimensio...
...Se Kit delivers a novel procedure for the uniform ...) labeling of whole genome DNA from small samples....and highly reproducible amplification and labeling...sists of a REPLI-g Mini Kit module (QIAGEN) and a ...
Biology Products: